Predictive value of amniotic fluid cystatin C levels for the early identification of fetuses with obstructive uropathies.
OBJECTIVE
To compare the diagnostic accuracy of cystatin C with that of creatinine in discriminating renal function in fetuses without ultrasononographic evidence of renal malformations from those with obstructive uropathies.


METHODS
Prospective, observational cohort study.


METHODS
Prenatal morphologic and functional evaluation of fetal obstructive uropathies throughout pregnancy.


METHODS
A total of 96 healthy pregnant women at different stages of pregnancy, without any pregnancy-related maternal disease. Eighty-one pregnant women without clinical and ultrasonographic evidence of any fetal anomaly, confirmed at birth, were defined as controls; 15 pregnant women with various fetal obstructive uropathies, evidenced by repeated ultrasound examinations and confirmed at birth, were defined as cases.


METHODS
Creatinine was measured by a kinetic Jaffe picric acid method and cystatin C by a nephelometric immunoassay. Variables were analysed by applying conventional statistical tests; the non-parametric receiver operating curves (ROC) analysis was used to evaluate the diagnostic efficiencies of the biochemical markers.


METHODS
Incidence of confirmed, diagnosed, neonatal obstructive uropathy by measuring baseline levels of cystatin C and creatinine in amniotic fluid.


RESULTS
Baseline levels of cystatin C in amniotic fluid were significantly higher (P = 0.0015) among cases than in controls with comparable gestational age; no significant difference was found for creatinine levels (P = n.s.). The maximum diagnostic accuracy of serum cystatin C in discriminating controls from fetal uropathies was 96%, while that of creatinine was 62%.


CONCLUSIONS
Cystatin C may be considered a sensitivebiochemical marker for the early identification of fetuses with obstructive uropathies.
Mussap
Michele
M
Department of Laboratory Medicine, University-Hospital of Padova, Padua, Italy.
Fanos
Vassilios
V
Pizzini
Carla
C
Marcolongo
Alma
A
Chiaffoni
Graziella
G
Plebani
Mario
M
D000328:Adult; D000653:Amniotic Fluid / Q000737:chemistry*; D015415:Biomarkers / Q000032:analysis; D015331:Cohort Studies; D003251:Constriction, Pathologic; D003404:Creatinine / Q000032:analysis; D055316:Cystatin C; D015891:Cystatins / Q000032:analysis*; D005260:Female; D005315:Fetal Diseases / Q000175:diagnosis* / Q000503:physiopathology; D005865:Gestational Age; D006801:Humans; D007668:Kidney / Q000002:abnormalities* / Q000196:embryology; D007674:Kidney Diseases / Q000175:diagnosis* / Q000503:physiopathology; D008297:Male; D011237:Predictive Value of Tests; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000379:methods; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D014463:Ultrasonography / Q000379:methods
D015415:Biomarkers; C525030:CST3 protein, human; D055316:Cystatin C; D015891:Cystatins; D003404:Creatinine